1. Home
  2. ARE vs RPRX Comparison

ARE vs RPRX Comparison

Compare ARE & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARE
  • RPRX
  • Stock Information
  • Founded
  • ARE 1994
  • RPRX 1996
  • Country
  • ARE United States
  • RPRX United States
  • Employees
  • ARE N/A
  • RPRX N/A
  • Industry
  • ARE Real Estate Investment Trusts
  • RPRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ARE Real Estate
  • RPRX Health Care
  • Exchange
  • ARE Nasdaq
  • RPRX Nasdaq
  • Market Cap
  • ARE 13.2B
  • RPRX 15.6B
  • IPO Year
  • ARE 1997
  • RPRX 2020
  • Fundamental
  • Price
  • ARE $84.93
  • RPRX $36.36
  • Analyst Decision
  • ARE Hold
  • RPRX Strong Buy
  • Analyst Count
  • ARE 8
  • RPRX 3
  • Target Price
  • ARE $114.00
  • RPRX $45.33
  • AVG Volume (30 Days)
  • ARE 1.2M
  • RPRX 3.9M
  • Earning Date
  • ARE 10-27-2025
  • RPRX 11-05-2025
  • Dividend Yield
  • ARE 6.22%
  • RPRX 2.42%
  • EPS Growth
  • ARE N/A
  • RPRX 54.86
  • EPS
  • ARE N/A
  • RPRX 2.32
  • Revenue
  • ARE $3,097,996,000.00
  • RPRX $2,305,243,000.00
  • Revenue This Year
  • ARE N/A
  • RPRX $33.77
  • Revenue Next Year
  • ARE N/A
  • RPRX $4.62
  • P/E Ratio
  • ARE N/A
  • RPRX $15.64
  • Revenue Growth
  • ARE 3.00
  • RPRX 3.02
  • 52 Week Low
  • ARE $67.37
  • RPRX $24.05
  • 52 Week High
  • ARE $125.63
  • RPRX $38.00
  • Technical
  • Relative Strength Index (RSI)
  • ARE 64.76
  • RPRX 50.51
  • Support Level
  • ARE $83.42
  • RPRX $35.97
  • Resistance Level
  • ARE $85.79
  • RPRX $36.94
  • Average True Range (ATR)
  • ARE 1.62
  • RPRX 0.83
  • MACD
  • ARE 0.30
  • RPRX 0.02
  • Stochastic Oscillator
  • ARE 85.77
  • RPRX 71.33

About ARE Alexandria Real Estate Equities Inc.

Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: